AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01282255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
Study NCT03380637 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
Study NCT02391311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
Study NCT02391311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
Study NCT00879723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin and Mineral supplementation
Description: IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg.
Study NCT02057367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scalp block with 0.9% normal saline
Description: Anterior scalp block will be done by using 0.9% normal saline 20 ml.
Study NCT01957293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: single oral administration, 4 mg
Study NCT01957293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral administration
Study NCT01618058 — intervention group
Intervention type: DRUG
Intervention: No Investigational Product
Description: This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants
Study NCT03340285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AkP06
Description: first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
Study NCT03340285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
Study NCT04555863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: haMSter smartphone app
Description: the app tracks patient reported outcomes
Study NCT01729104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I.
Study NCT03752996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TF™ Aortic Valve System
Description: Transcatheter Aortic Valve Implantation
Study NCT04348812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: mobile attention bias modification training for anxiety, using the app Personal Zen
Study NCT04348812 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ABMT
Description: mobile attention bias modification training for anxiety, using the app Personal Zen
Study NCT04348812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
Study NCT01322854 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
Study NCT01322854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
Study NCT00620373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study NCT00620373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Mammography
Description: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
Study NCT00620373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium (99mTc) sestamibi
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Study NCT02871349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
Study NCT02871349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
Study NCT02871349 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: An MRI will be performed on participants aged 15-24 years.
Study NCT01729104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
Study NCT01729104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
Study NCT00821860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: Talc pleurodesis
Study NCT00821860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic thoracoscopy
Description: Talc pleurodesis via thoracoscopy
Study NCT00821860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic videothoracoscopy
Description: Video-assisted thoracoscopic pleurectomy
Study NCT02621255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia type of performed for patient which has femur fracture.
Study NCT01747070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS and EAC sham
Description: The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
Study NCT01747070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tDCS sham and EAC sham
Description: For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
Study NCT02621255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Anesthesia type of performed for patient which has femur fracture.
Study NCT00042458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
Study NCT00042458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
Study NCT02519335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
Study NCT03543241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MyoStrain
Description: Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
Study NCT00758680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
Study NCT02871349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: An MRI will be performed on participants aged 15-24 years.
Study NCT00688467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
Study NCT00688467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
Study NCT01461499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
Study NCT01461499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: any angiotensin receptor blockers
Description: The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
Study NCT03051464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete responders and Non-complete responders
Description: Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
Study NCT03051464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation + EBRT Boost
Description: 45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
Study NCT03051464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation + HDRBT Boost
Description: 45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
Study NCT05434793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RJ-LASER, LASERPEN®; Reimers & Janssen, Germany
Description: The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
Study NCT03461562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
Study NCT03461562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
Study NCT02181946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study NCT02181946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02524236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection in the prostate
Description: transrectal access of prostatic injection
Study NCT01520649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
Study NCT01520649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose capsules
Description: The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
Study NCT04328545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on DLPFC
Description: Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
Study NCT04328545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS on M1
Description: Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
Study NCT04328545 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
Study NCT01747070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS sham and EAC
Description: For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
Study NCT01747070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS and EAC
Description: For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
Study NCT05276336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency turbinate reduction
Description: Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
Study NCT05276336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacology treatment
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Study NCT00273624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 10 mg Olanzapin concurrent to antidepressive medication
Study NCT00273624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00574834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 20 mg once daily for 6 months
Study NCT00574834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ-hydrochlorothiazide
Description: HCTZ 25 mg once daily for 6 months
Study NCT00574834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril+HCTZ
Description: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
Study NCT05276336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacology treatment
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Study NCT04346186 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IgM and IgG diagnostic kits to SARS-CoV-2
Description: Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
Study NCT04346186 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa-test for IgM and IgG to SARS-CoV-2
Description: Elisa-test for IgM and IgG to SARS-CoV-2
Study NCT01453452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
Study NCT00867256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large Diameter Metal on Metal
Study NCT00017472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: apolizumab
Description: Given IV
Study NCT00017472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00017472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02121002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Topical Gel, 1%
Description: Opaque, white gel
Study NCT02121002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren Topical Gel, 1%
Description: Opaque, white gel
Study NCT02121002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Diclofenac Sodium Topical Gel
Description: Opaque, white gel
Study NCT00275392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: vestibular adaptation and substitution exercises
Study NCT00275392 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vestibular exercises
Study NCT04553458 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of the tumour
Study NCT04553458 — intervention group
Intervention type: DRUG
Intervention: Trance-arterial chemoembolization
Description: Trance-arterial chemotherapy
Study NCT04553458 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: non-anatomical or anatomical liver resection
Study NCT04553458 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Combined radiofrequency ablation + percutaneous ethanol injection
Description: combined therapy
Study NCT04553458 — intervention group
Intervention type: DRUG
Intervention: Percutaneous ethanol injection
Description: Percutaneous ethanol injection of HCC
Study NCT04553458 — intervention group
Intervention type: DRUG
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy
Study NCT04553458 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib
Study NCT04553458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Viscum
Description: Viscum for HCC
Study NCT00758680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo comparator
Description: Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
Study NCT03393806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3772847
Description: GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.